Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Liabilities: 2017-2024

Historic Other Non-Current Liabilities for Seres Therapeutics (MCRB) over the last 8 years, with Dec 2024 value amounting to $1.8 million.

  • Seres Therapeutics' Other Non-Current Liabilities rose 12.96% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 12.96%. This contributed to the annual value of $1.8 million for FY2024, which is 12.90% up from last year.
  • As of FY2024, Seres Therapeutics' Other Non-Current Liabilities stood at $1.8 million, which was up 12.90% from $1.6 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Other Non-Current Liabilities peaked at $11.5 million during FY2021, and registered a low of $1.0 million during FY2020.
  • Over the past 3 years, Seres Therapeutics' median Other Non-Current Liabilities value was $1.6 million (recorded in 2023), while the average stood at $1.6 million.
  • In the last 5 years, Seres Therapeutics' Other Non-Current Liabilities spiked by 1,046.06% in 2021 and then plummeted by 87.46% in 2022.
  • Over the past 5 years, Seres Therapeutics' Other Non-Current Liabilities (Yearly) stood at $1.0 million in 2020, then skyrocketed by 1,046.06% to $11.5 million in 2021, then tumbled by 87.46% to $1.4 million in 2022, then rose by 12.90% to $1.6 million in 2023, then rose by 12.90% to $1.8 million in 2024.